Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Triplet Combo Well-Tolerated, Effective for IDH1-Mutated AML

Courtney DiNardo, MD, MSCE, The University of Texas MD Anderson Cancer Center, Houston, discusses the promising results from a phase 1b/2 study exploring ivosidenib in combination with venetoclax and azacitidine for IDH1-mutated acute myeloid leukemia (AML). These results were presented at the virtual 2020 ASCO Annual Meeting.

 

Advertisement

Advertisement

Advertisement

Advertisement